292 related articles for article (PubMed ID: 25575025)
1. Persistence of frequently transmitted drug-resistant HIV-1 variants can be explained by high viral replication capacity.
Pingen M; Wensing AM; Fransen K; De Bel A; de Jong D; Hoepelman AI; Magiorkinis E; Paraskevis D; Lunar MM; Poljak M; Nijhuis M; Boucher CA;
Retrovirology; 2014 Nov; 11():105. PubMed ID: 25575025
[TBL] [Abstract][Full Text] [Related]
2. Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine.
García-Lerma JG; MacInnes H; Bennett D; Weinstock H; Heneine W
J Virol; 2004 Jul; 78(14):7545-52. PubMed ID: 15220429
[TBL] [Abstract][Full Text] [Related]
3. HIV-1 Transmitted Drug Resistance Mutations in Newly Diagnosed Antiretroviral-Naive Patients in Turkey.
Sayan M; Sargin F; Inan D; Sevgi DY; Celikbas AK; Yasar K; Kaptan F; Kutlu S; Fisgin NT; Inci A; Ceran N; Karaoglan I; Cagatay A; Celen MK; Koruk ST; Ceylan B; Yildirmak T; Akalın H; Korten V; Willke A
AIDS Res Hum Retroviruses; 2016 Jan; 32(1):26-31. PubMed ID: 26414663
[TBL] [Abstract][Full Text] [Related]
4. Effect on HIV-1 viral replication capacity of DTG-resistance mutations in NRTI/NNRTI resistant viruses.
Pham HT; Mesplède T; Wainberg MA
Retrovirology; 2016 Apr; 13(1):31. PubMed ID: 27130466
[TBL] [Abstract][Full Text] [Related]
5. The HIV-1 protease substitution K55R: a protease-inhibitor-associated substitution involved in restoring viral replication.
Margerison ES; Maguire M; Pillay D; Cane P; Elston RC
J Antimicrob Chemother; 2008 Apr; 61(4):786-91. PubMed ID: 18252693
[TBL] [Abstract][Full Text] [Related]
6. Effect of HIV constructs containing protease-reverse transcriptase fusion proteins on viral replication.
Cherry E; Morin N; Wainberg MA
AIDS; 1998 Jun; 12(9):967-75. PubMed ID: 9662192
[TBL] [Abstract][Full Text] [Related]
7. Diminished transmission of drug resistant HIV-1 variants with reduced replication capacity in a human transmission model.
Pingen M; Sarrami-Forooshani R; Wensing AM; van Ham P; Drewniak A; Boucher CA; Geijtenbeek TB; Nijhuis M
Retrovirology; 2014 Dec; 11():113. PubMed ID: 25499671
[TBL] [Abstract][Full Text] [Related]
8. High incidence of non-B and recombinant HIV-1 strains in newly diagnosed patients in Galicia, Spain: study of genotypic resistance.
Pérez-Alvarez L; Carmona R; Muñoz M; Delgado E; Thomson MM; Contreras G; Pedreira JD; Rodríguez Real R; Vázquez de Parga E; Medrano L; Taboada JA; Nájera R;
Antivir Ther; 2003 Aug; 8(4):355-60. PubMed ID: 14518705
[TBL] [Abstract][Full Text] [Related]
9. Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1.
Bleiber G; Munoz M; Ciuffi A; Meylan P; Telenti A
J Virol; 2001 Apr; 75(7):3291-300. PubMed ID: 11238855
[TBL] [Abstract][Full Text] [Related]
10. Evidence of a role for the Q151L mutation and the viral background in development of multiple dideoxynucleoside-resistant human immunodeficiency virus type 1.
García-Lerma JG; Gerrish PJ; Wright AC; Qari SH; Heneine W
J Virol; 2000 Oct; 74(20):9339-46. PubMed ID: 11000201
[TBL] [Abstract][Full Text] [Related]
11. High prevalence of HIV-1 transmitted drug-resistance mutations from proviral DNA massively parallel sequencing data of therapy-naïve chronically infected Brazilian blood donors.
Pessôa R; Sanabani SS
PLoS One; 2017; 12(9):e0185559. PubMed ID: 28953964
[TBL] [Abstract][Full Text] [Related]
12. Infectivity and replication capacity of drug-resistant human immunodeficiency virus type 1 variants isolated during primary infection.
Simon V; Padte N; Murray D; Vanderhoeven J; Wrin T; Parkin N; Di Mascio M; Markowitz M
J Virol; 2003 Jul; 77(14):7736-45. PubMed ID: 12829813
[TBL] [Abstract][Full Text] [Related]
13. Effect of polymorphisms on the replicative capacity of protease inhibitor-resistant HIV-1 variants under drug pressure.
Suñé C; Brennan L; Stover DR; Klimkait T
Clin Microbiol Infect; 2004 Feb; 10(2):119-26. PubMed ID: 14759236
[TBL] [Abstract][Full Text] [Related]
14. Infection with the frequently transmitted HIV-1 M41L variant has no influence on selection of tenofovir resistance.
Pingen M; Nijhuis M; Mudrikova T; van Laarhoven A; Langebeek N; Richter C; Boucher CA; Wensing AM
J Antimicrob Chemother; 2015 Feb; 70(2):573-80. PubMed ID: 25261422
[TBL] [Abstract][Full Text] [Related]
15. Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1.
Hu Z; Giguel F; Hatano H; Reid P; Lu J; Kuritzkes DR
J Virol; 2006 Jul; 80(14):7020-7. PubMed ID: 16809307
[TBL] [Abstract][Full Text] [Related]
16. Persistence of HIV-1 variants with multiple protease inhibitor (PI)-resistance mutations in the absence of PI therapy can be explained by compensatory fixation.
van Maarseveen NM; Wensing AM; de Jong D; Taconis M; Borleffs JC; Boucher CA; Nijhuis M
J Infect Dis; 2007 Feb; 195(3):399-409. PubMed ID: 17205479
[TBL] [Abstract][Full Text] [Related]
17. A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism.
Nijhuis M; van Maarseveen NM; Lastere S; Schipper P; Coakley E; Glass B; Rovenska M; de Jong D; Chappey C; Goedegebuure IW; Heilek-Snyder G; Dulude D; Cammack N; Brakier-Gingras L; Konvalinka J; Parkin N; Kräusslich HG; Brun-Vezinet F; Boucher CA
PLoS Med; 2007 Jan; 4(1):e36. PubMed ID: 17227139
[TBL] [Abstract][Full Text] [Related]
18. Impact of human immunodeficiency virus type 1 reverse transcriptase inhibitor drug resistance mutation interactions on phenotypic susceptibility.
Trivedi V; Von Lindern J; Montes-Walters M; Rojo DR; Shell EJ; Parkin N; O'Brien WA; Ferguson MR
AIDS Res Hum Retroviruses; 2008 Oct; 24(10):1291-300. PubMed ID: 18844463
[TBL] [Abstract][Full Text] [Related]
19. Altered replicative capacity of recombinant HIV type 1 containing mutations at codons 26 and 29 of the viral protease.
Melón S; Gil-Roda C; de Oña M; Erice A
AIDS Res Hum Retroviruses; 2004 Nov; 20(11):1183-8. PubMed ID: 15588340
[TBL] [Abstract][Full Text] [Related]
20. Comparison between next-generation and Sanger-based sequencing for the detection of transmitted drug-resistance mutations among recently infected HIV-1 patients in Israel, 2000-2014.
Moscona R; Ram D; Wax M; Bucris E; Levy I; Mendelson E; Mor O
J Int AIDS Soc; 2017 Aug; 20(1):21846. PubMed ID: 28799325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
